secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEXGEL, INC. (NXGL)
CIK:        0001468929
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001493152-24-012173
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NEXGEL reports FY2023 revenue $4.1M (+99.7% YoY); net loss narrows to $3.2M
---------------------------------------------------------------------------

- Revenue $4.1M for FY2023, up 99.7% YoY; Q4 revenue $1.1M, up 110% YoY.
- Net loss $3.2M vs $4.7M prior year; gross profit margin improved to 15.2% from 12.5%.
- Ended FY2023 with $2.7M cash; subsequent $1M insider-led direct offering closed.
- Q1 2024 revenue guided to ~$1.25M, excluding $176K AbbVie deposit.
- Key operational milestones: JV with CG Converting, AbbVie gel pad supply agreement, Kenkoderm acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468929/000149315224012173/0001493152-24-012173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468929/000149315224012173/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-012173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer